Deokbae Park1, Youngki Lee1. 1. Dept. of Histology, Jeju National University School of Medicine, Jeju 690-756, Korea.
Abstract
Autophagy is a homeostatic degradation process that is involved in tumor development and normal development. Autophagy is induced in cancer cells in response to chemotherapeutic agents, and inhibition of autophagy results in enhanced cancer cell death or survival. Chloroquine (CQ), an anti-malarial devrepug, is a lysosomotropic agent and is currently used as a potential anticancer agent as well as an autophagy inhibitor. Here, we evaluate the characteristics of these dual activities of CQ using human colorectal cancer cell line HCT15. The results show that CQ inhibited cell viability in dose-and time-dependent manner in the range between 20 to 80 uM, while CQ did not show any antiproliferative activity at 5 and 10 uM. Cotreatment of CQ with antitumor agent NVP-BEZ235, a dual inhibitor of PI3K/mTOR, rescued the cell viability at low concentrations meaning that CQ acted as an autophagy inhibitor, but CQ induced the lethal effect at high concentrations. Acridine orange staining revealed that CQ at high doses induced lysosomal membrane permeabilization (LMP). High doses of CQ produced cellular reactive oxygen species (ROS) and cotreatment of antioxidants, such as NAC and trolox, with high doses of CQ rescued the cell viability. These results suggest that CQ may exert its dual activities, as autophagy inhibitor or LMP inducer, in concentration-dependent manner.
Autophagy is a homeostatic degradation process that is involved in tumor development and normal development. Autophagy is induced in cancer cells in response to chemotherapeutic agents, and inhibition of autophagy results in enhanced cancer cell death or survival. Chloroquine (CQ), an anti-malarial devrepug, is a lysosomotropic agent and is currently used as a potential anticancer agent as well as an autophagy inhibitor. Here, we evaluate the characteristics of these dual activities of CQ using humancolorectal cancer cell line HCT15. The results show that CQ inhibited cell viability in dose-and time-dependent manner in the range between 20 to 80 uM, while CQ did not show any antiproliferative activity at 5 and 10 uM. Cotreatment of CQ with antitumor agent NVP-BEZ235, a dual inhibitor of PI3K/mTOR, rescued the cell viability at low concentrations meaning that CQ acted as an autophagy inhibitor, but CQ induced the lethal effect at high concentrations. Acridine orange staining revealed that CQ at high doses induced lysosomal membrane permeabilization (LMP). High doses of CQ produced cellular reactive oxygen species (ROS) and cotreatment of antioxidants, such as NAC and trolox, with high doses of CQ rescued the cell viability. These results suggest that CQ may exert its dual activities, as autophagy inhibitor or LMP inducer, in concentration-dependent manner.
Autophagy is a multistep catabolic process that occurs during nutrient deprivation,
metabolic stresses, tumor growth, normal mammalian development and differentiation
(Degenhardt et al., 2006, Mizushima & Levine, 2010). It begins
with the formation of double-membrane vesicles, autophagosomes, which engulf
cytoplasmic constituents. The autophagosomes fuse with lysosomes, where the damaged
or long-lived proteins and organelles are degraded and recycled as a protective
mechanism and adaptive response to stressful conditions (Degenhardt et al., 2006). Excessive and sustained activation of
autophagy, however, seems to provoke cell demise (autophagic cell death) by
depleting cell organelles and critical proteins. Consistent with its function to
either induce cell death or promote cell survival, several lines of evidence suggest
the paradoxical role of autophagy in cancer cells induced by a variety of
anti-cancer drugs, with response enhancing or counteracting their anticancer effect
(Degenhardt et al., 2006).Chloroquine (CQ) is one of lysosomotropic agents as a weak basic amine. It can freely
diffuse across lysosomal membranes in uncharged form but can also become protonated
and trapped within acidic vesicles such as lysosomes. The protonation of CQ results
in inhibition of hydrolytic lysosomal enzymes by perturbing the acidic milieu
(pH<5) of lysosome, which has made CQ an useful drug in the treatment of
malaria (Kroemer & Jaattela, 2005). CQ
can suppress autophagy by accumulating in the lysosomal lumen and inhibiting the
autophagolysosome formation (Boya & Kroemer,
2008). Since several current studies have revealed that tumor resistance
to anticancer therapies including radiation therapy, chemotherapy and molecular
targeted therapies is attributed to upregulation of autophagy as a protective
mechanism (Hu et al., 2012; Zou et al., 2012), CQ and its derivative
hyroxychloroquine have been used as an autophagy inhibitor available for clinical
trials of cancerpatients. In addition, inhibition of autophagy by CQ
synergistically augments cytotoxicity in combination with several anticancer drugs
in preclinical models (Takeuchi et al., 2005;
Syelo et al., 2006; Carew et al., 2007; Xu et al.,
2011; Firat et al., 2012).
Recently, however, evidence has been accumulated suggesting that the ability of CQ
to inhibit autophagy by blocking autophagolysosome formation may not be the only
mechanism by which it exerts antitumor effect. Lysosomotropic CQ sensitizes breast
cancer cells to chemotherapy independent of autophagy since autophagy blockage by
knocking out autophagy gene such as Atg12 and Beclin 1, or bafilomycin A1 treatment
did not show any sensitization effect to chemotherapy (Maycotte et al., 2012). Another report also showed that
PI3K/mTOR inhibitor PI103 enhances the lysosomal compartment by increasing its size
and function, while CQ destabilizes lysosomal membranes (Enzenmuller et al., 2013). When the accumulation of protonated
CQ within lysosomes reaches above a certain threshold, it attains the detergentlike
activity and leads to lysosomal membrane permeabilization (LMP) (Boya & Kroemer, 2008). LMP releases the
cathepsins and other hydrolytic enzymes from lysosomal lumen into the cytosol, which
can result in apoptosis with mitochondrial outer membrane permeabilization and
caspases activation, or in necrosis depending on the extent of LMP and the cell
context (Kroemer & Jaattela, 2005;
Boya & Kroemer, 2008).Thus the present study was undertaken to demonstrate the properties and underlying
mechanism for the dual activities of CQ, autophagy inhibitor or LMP inducer, by
using humancolorectal cancer cell line HCT15.
MATERIALS & METHODS
Cell culture and reagents
The humancolorectal cancer cell line HCT15 was obtained from the American Type
Culture Collection (Manassas, VA). Cells were grown in a monolayer culture in
DMEM (Sigma) supplemented with 10% fetal bovine serum (Sigma) and 1%
streptomycin/penicillin, and were maintained at 37°C in a humidified
atmosphere consisting of 5 % CO2 and 95% air. Cells were regularly
tested for mycoplasma contamination by treating 5 ug/mL of Plasmocin
(InvivoGen). NVP-BEZ235 was purchased from LC laboratories (Woburn, MA). CQ,
N-acetylcysteine (NAC), trolox, acridine orange,
3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and
Hoechst33342 were all purchased from Sigma and Image-iT LIVE Green Reactive
Oxygen Species Detection Kit was from Molecular Probes.
Cell viability assay
To determine the effects of CQ and/or NVP-BEZ235 on HCT15 cell viability after
the treatments, we used MTT assay as described previously (Song et al., 2011). Cells were harvested and seeded at 4
× 104 cells per well (0.5 mL) in 24-well plates and incubated
overnight at 37°C. The cells were then incubated for 48 hours with CQ
and/or NVP-BEZ235, or for 12, 24, 48, and 72 hours with CQ to determine the
dose- and time-dependent cell survival rate. Then the cells were incubated with
MTT reagent for 3 hours at 37°C, followed by solubilization of the
formazan crystal with propanol for 30 minutes. Absorbance was measured at 570 nm
with a microplate analyzer. All the experiments were performed in
triplicate.
Detection of acidic vesicular organelles with acridine orange
staining
The characteristics of autophagy is the formation of acidic vesicular organelle
(AVO) which consist predominantly of autophagosome and autophagolysosome. To
visualize the development of AVOs after CQ treatment, we performed vital
staining with acridine orange. Briefly cells were washed twice with D-PBS,
stained with acridine orange (1 ug/mL) in HBSS containing 5% FBS for 15 minutes
and then observed with a fluorescence microscope.
Statistical analysis
Data were expressed in the form of mean ± SEM. The statistical analysis
was done using Student's t Test. Differences between
means were considered as significant when yielding p <
0.05.
RESULTS
Effects of CQ on the cell viability of colorectal cancer cells
To test the effect of CQ on the survival of colorectal cancer cells, we treated
HCT15 cell line harboring PI3K and K-Ras mutation with CQ at concentrations of 5
uM to 80 uM for 12, 24, 48, or 72 hours and then antiproliferative activity of
CQ was measured by using MTT assay. As shown in Fig. 1, CQ inhibited cell viability in dose- and time-dependent
manners in the range of CQ concentration between 20 to 80 uM, whereas it did not
show antiproliferative activity at 5 and 10 uM.
Fig. 1.
Dose- and time-dependent effect of CQ on the growth of HCT15
cells. HCT15 cells were treated with various concentrations
of CQ for 12, 24, 48, and 72 hours. Cell viability was determined by MTT
assay. Experiments were performed in triplicate. Error bars, SEM.
Dose- and time-dependent effect of CQ on the growth of HCT15
cells. HCT15 cells were treated with various concentrations
of CQ for 12, 24, 48, and 72 hours. Cell viability was determined by MTT
assay. Experiments were performed in triplicate. Error bars, SEM.
CQ shows differential effects on colorectal cancer cells in a
concentration-dependent fashion
There has been some conflicting results and interpretation about the effects of
CQ treatment on cancer cells, which seem to be due to the varied concentrations
of CQ treated (Xu et al., 2011; Seitz et al., 2013). CQ is not only an
autophagy inhibitor by blocking the fusion of autophagosome and lysosome in the
late stage of autophagy, but it can lead to cell death since the protonated form
of CQ reaching above a certain threshold acquires detergent-like properties,
which results in lethal lysosomal destabilization known as LMP (Boya & Kroemer, 2008). Therefore, we
hypothesized that CQ may act as an autophagy inhibitor at a low concentration,
but as an LMP inducer at a high concentration above the threshold attaining
detergent-like activity. To prove this, we employed HCT15 cell line, since our
unpublished study showed that autophagy inhibition by CQ rescued the HCT15 cell
viability in cotreatment regimen with anticancer drug NVP-BEZ235 (BEZ235) of a
dual inhibitor of PI3K and mTOR (Maira et al.,
2008). As revealed in Fig. 2A,
CQ at low concentrations (10–20 uM) seemed to exert its effect as an autophagy
inhibitor by rescuing the cell viability by both CQ treatment and cotreatment
with CQ and NVP-BEZ235, while it induced the lethal effect at high
concentrations (40–160 uM). Next, we tried to monitor the development of AVOs as
a function of CQ concentration by staining cells with acridine orange. Acridine
orange (AO) is a lysosomotropic metachromatic fluorochrome, which emits red
fluorescence at high concentrations when in lysosomes and green fluorescence at
low concentrations in cytoplasm and nucleus. Therefore, reduced red fluorescence
in lysosomes of AO-loaded cells can reflect LMP (Antunes et al., 2001). The untreated HCT15tumor cells showed little
cytoplasmic staining. Notably, treatment of the tumor cells with a low
concentration (10 uM) of CQ exhibited the development of abundant red
fluorescent AVOs, revealing autophagy inhibition effect. Meanwhile, reduced red
or green fluorescence together with enlargement of AVOs was observed after
applying a high concentration of CQ treatment, raising the possibility of LMP
induction (Fig. 2B).
Fig. 2.
Concentration-dependent effects of CQ on HCT15 cells. (A)
HCT15 cell lines were treated with various concentrations of CQ and CQ
plus BEZ235 (5 nM) for 48 hours. Cell viability was analyzed by MTT
assay. (B) HCT15 cells were treated with 0, 10 and 100 uM of CQ for 24
hours, stained with 1 ug/mL acridine orange and then observed under
fluorescence microscope. All experiments were repeated three times. Bar,
10 um. Error bars, SEM. *, p<0.05.
Concentration-dependent effects of CQ on HCT15 cells. (A)
HCT15 cell lines were treated with various concentrations of CQ and CQ
plus BEZ235 (5 nM) for 48 hours. Cell viability was analyzed by MTT
assay. (B) HCT15 cells were treated with 0, 10 and 100 uM of CQ for 24
hours, stained with 1 ug/mL acridine orange and then observed under
fluorescence microscope. All experiments were repeated three times. Bar,
10 um. Error bars, SEM. *, p<0.05.
CQ induces production of ROS and antioxidants increase cell viability
Since reactive oxygen species (ROS) can regulate the induction of autophagy and
LMP (Terman & Kurz, 2006; Scherz-Schouval et al., 2007), we
investigated whether ROS is generated in response to the high concentration of
CQ treatment and whether ROS production contributes to the cell viability. We
used the general ROS scavenger N-acetylcysteine (NAC), a precursor of the
antioxidant glutathione that has antioxidant effects via its thiol group (Zafarullah et al., 2006), and trolox, a
derivative of the antioxidant vitamine E (Seifried et al., 2003). At high concentrations of CQ, both NAC and
trolox resulted in the rescue of cell viability (Fig. 3A). We next analyzed the generation of ROS upon treatment
of CQ using the Image-iT Live green ROS detection kit. Increased cellular ROS
were detected following high concentration of CQ treatment, but the low
concentration of CQ treatment showed little ROS positive signal (Fig. 3B).
Fig. 3.
Antioxidants increase the cell viability and ROS is produced
following CQ treatment. (A) HCT15 cells were treated with
various concentrations of CQ plus DMSO, 10 mM NAC and 500 uM trolox.
Cell viability was analyzed by MTT assay. (B) HCT 15 cells were treated
with 0, 10 and 100 uM of CQ for 24 hours. Cellular ROS production was
examined with the Image-iT Live Green ROS Detection kit and visualized
under fluorescence microscope. Experiments were performed in triplicate.
Bar, 10 um. Error bars, SEM. *, p<0.05,
**, p <0.01.
Antioxidants increase the cell viability and ROS is produced
following CQ treatment. (A) HCT15 cells were treated with
various concentrations of CQ plus DMSO, 10 mM NAC and 500 uM trolox.
Cell viability was analyzed by MTT assay. (B) HCT 15 cells were treated
with 0, 10 and 100 uM of CQ for 24 hours. Cellular ROS production was
examined with the Image-iT Live Green ROS Detection kit and visualized
under fluorescence microscope. Experiments were performed in triplicate.
Bar, 10 um. Error bars, SEM. *, p<0.05,
**, p <0.01.
DISCUSSION
The present study, using humancolon cancer cell line HCT15 harboring PIK3CA and
K-Ras mutations, was undertaken to evaluate the nature of anticancer effect of CQ.
Our results show that CQ has biphasic activity depending on its concentrations
treated; CQ at low concentrations seems to act as an autophagy inhibitor while
acting as an LMP inducer at high concentrations. In addition, treatment of CQ leads
to increased generation of ROS. Also, addition of antioxidants such as NAC and
trolox rescues the tumor cell viability in response to high doses of CQ.We first screened the antiproliferative effect of CQ by MTT assay. Our results
revealed that exposure of HCT15cancer cells to CQ inhibits the cell viability in a
dose- and time-dependent manner. Interestingly, a low concentration of CQ treatment
increases cell survival. Cancer cells activate autophagy in response to high
metabolic rate associated with rapid cell proliferation (Yang et al., 2011). Humancancer cell lines with activating
mutations in Ras commonly have high levels of basal autophagy even in the presence
of abundant nutrients (Guo et al., 2011).
Moreover, the expression of oncogenically mutated Ras gene induces cell death with
morphological and biochemical characteristics typical of autophagic cell death in
humanglioma and gastric cancer cell line (Chi et
al., 1999). The persistent and excessive autophagy can lead to autophagic
cell death (type II physiological cell death) depending on the cellular context
(Li et al., 2013). Thus, considering that
the colorectal cancer cell line of HCT15 includes K-Ras mutation in addition to
phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) mutation, the
autophagic cell death of tumor cells may manifest in the normal replete conditions,
which is suppressed by low concentrations of CQ. This notion is further confirmed by
the combination treatment of CQ with antitumor agent BEZ235. Autophagy is negatively
regulated by mTOR and inhibition of mTOR with BEZ235 stimulates the autophagy in
cancer cells, in which autophagy acts in either prodeath or prosurvival manners
(Xu et al., 2011; Li et al., 2013). Our unpublished data showed that cotreatment
of BEZ235 with low doses of CQ (5–20 uM) rescues the viability of HCT15cancer
cells, which enables us to use as an experimental model to delineate the
dosedependent dual activities of CQ, i.e., autophagy inhibitor or LMP inducer in a
dose-dependent manner. Our present data indicate that CQ at low concentrations
counteracts the antitumor effect of BEZ235, while high concentrations of CQ results
in LMP induction. This is consistent with a recent study using a relatively high
concentration of CQ (50 uM) that cotreatment of BEZ235 with CQ triggers LMP and
apoptosis via mitochondrial-lysosomal cross-talk (Seitz et al., 2013). They demonstrate that inhibition of
BEZ235-stimulated autophagy by silencing or knockdown of autophagy-related genes
such as Atg7 or Atg5 do not alter the induction of apoptosis by the combination
treatment with BEZ235 plus CQ. Together, our present results and others suggest that
the outcome of CQ cotreatment with other anticancer drugs might not be due to the CQ
effect on autophagy induced by the chemotherapeutic agents, as the effect may be
resulted from mechanisms other than its autophagy inhibition, such as LMP
induction.Recently, it has been suggested that ROS results in induction of autophagy and LMP
(Terman & Kurz, 2006; Scherz-Schouval et al., 2007). The present
study is, to our knowledge, the first report to show production of cellular ROS in
response to CQ in colorectal cancer cells although underlying mechanism of
CQ-mediated ROS producion is unclear. A number of cancer cell lines, including colon
cancer cells, have elevated steady state levels of mitochondrial superoxide relative
to normal epithelial cells (Aykin-Burns, et al.,
2009). Superoxide does not readily traverse the mitochondrial membrane
and the decreased manganese superoxide dismutase (SOD) activity and expression have
been reported in colorectal cancer cells (Bernard et
al., 1997), leading to the accumulation of superoxide in the
mitochondria. It is, therefore, plausible that the increased permeability of
mitochondrial membrane by cathepsins liberated from lysosome after LMP induction in
response to CQ treatment may be responsible for the translocation of mitochondrial
superoxide to cytoplasm, where it is converted to H2O2 and
other ROS by cytoplasmic copper/ zinc SOD. However, this speculation awaits further
experimental verification.Taken together, the present study suggests that low doses of CQ exert its effect as
an autophagic inhibitor and CQ at high doses acts as an LMP inducer leading to cell
death. In addition, there may be three possible modes for the anticancer effect by
high doses of CQ in HCT15colorectal cancer cells: 1) by LMP induction by
detergentlike activity of protonated CQ that is accumulated above a certain
threshold in lysosomes, 2) by autophagic cell death due to excessive and sustained
autophagy, which is attributed to the high level of basal autophagy by Ras mutation
in HCT15 cell line and additional induction of autophagy in response to ROS produced
by CQ treatment, 3) by LMP induction in response to ROS produced by CQ treatment.
However, our finding on the biphasic activities of CQ needs further investigation
for the ongoing clinical trials where CQ is used simply as an autophagy
inhibitor.
Authors: S Chi; C Kitanaka; K Noguchi; T Mochizuki; Y Nagashima; M Shirouzu; H Fujita; M Yoshida; W Chen; A Asai; M Himeno; S Yokoyama; Y Kuchino Journal: Oncogene Date: 1999-04-01 Impact factor: 9.867
Authors: Jennifer S Carew; Steffan T Nawrocki; Charissa N Kahue; Hui Zhang; Chunying Yang; Linda Chung; Janet A Houghton; Peng Huang; Francis J Giles; John L Cleveland Journal: Blood Date: 2007-03-15 Impact factor: 22.113
Authors: Samantha J Mascuch; Paul D Boudreau; Tristan M Carland; N Tessa Pierce; Joshua Olson; Mary E Hensler; Hyukjae Choi; Joseph Campanale; Amro Hamdoun; Victor Nizet; William H Gerwick; Teresa Gaasterland; Lena Gerwick Journal: J Nat Prod Date: 2017-12-07 Impact factor: 4.050
Authors: Barry E Kennedy; Michael Giacomantonio; J Patrick Murphy; Samuel Cutler; Maryanne Sadek; Prathyusha Konda; Joao A Paulo; Gopal P Pathak; Saskia H J Renkens; Stacy Grieve; Jonathan Pol; Steven P Gygi; Christopher Richardson; Daniel Gaston; Anthony Reiman; Guido Kroemer; Manal O Elnenaei; Shashi A Gujar Journal: Mol Ther Oncolytics Date: 2022-02-20 Impact factor: 7.200
Authors: María Ovejero-Sánchez; Jorge Rubio-Heras; María Del Carmen Vicente de la Peña; Laura San-Segundo; Jesús Pérez-Losada; Rogelio González-Sarmiento; Ana Belén Herrero Journal: Int J Mol Sci Date: 2022-07-07 Impact factor: 6.208
Authors: Edward J Calabrese; Jaap C Hanekamp; Yannic N Hanekamp; Rachna Kapoor; Gaurav Dhawan; Evgenios Agathokleous Journal: Sci Total Environ Date: 2020-09-25 Impact factor: 7.963